Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
31
Oct
Eisai Co.,Ltd. JP3160400002
2026-10-30 Eisai Co.,Ltd. “At the 19th Conference on Clinical Trials for Alzheimer's Disease (CTAD), we presented 5-year data on recanemab and real-world clinical research on Alzheimer's disease.”
31
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-30 Shionogi & Co.,Ltd. “(Correction/Correction of numerical data) Regarding a partial correction to the "Notice Regarding Revisions (Increase in Dividend) to Earnings Forecast and Annual Dividend Forecast for the Fiscal Year Ending March 2027".”
31
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-30 Shionogi & Co.,Ltd. “Notice regarding interim dividend.”
31
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-30 Sumitomo Pharma Co.,Ltd. “Notice Regarding Revision of Year-End Dividend Forecast for the Fiscal Year Ending March 2027.”
31
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-30 Sumitomo Pharma Co.,Ltd. “Notice Regarding Differences Between Consolidated Earnings Forecast and Actual Results for the Second Quarter (Interim) of the Fiscal Year Ending March 2027, and Revisions to the Full-Year Consolidated Earnings Forecast.”
31
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-30 Sumitomo Pharma Co.,Ltd. “Financial Statements for the second quarter of fiscal year 2027 (interim period) via SMS [IFRS] (link).”
31
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-30 Sumitomo Pharma Co.,Ltd. “Supplementary materials for the second quarter financial results (IFRS) for fiscal year 2026 (ending March 2027).”
31
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-30 Sumitomo Pharma Co.,Ltd. “Financial Results Presentation Materials for the Second Quarter of Fiscal Year 2026 (Ending March 2027).”
30
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-29 Shionogi & Co.,Ltd. “We have posted our financial results summary and supplementary materials for the second quarter of fiscal year 2026.”
30
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-29 Shionogi & Co.,Ltd. “We have posted the financial results presentation materials for the second quarter of fiscal year 2026.”
30
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-29 Shionogi & Co.,Ltd. “Announcement Regarding Revisions (Increase in Dividend) to Earnings Forecast and Annual Dividend Forecast for the Fiscal Year Ending March 2027.”
30
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-29 Shionogi & Co.,Ltd. “Regarding the conclusion of a stock transfer agreement with Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. for the transfer of the generic drug business in China.”
30
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-29 Shionogi & Co.,Ltd. “Notice regarding dividend distribution (interim dividend) from retained earnings.”
29
Oct
Eisai Co.,Ltd. JP3160400002
2026-10-28 Eisai Co.,Ltd. “Regarding sales revenue (preliminary report) for the anti-amyloid-beta antibody "Rekenbi®".”
29
Oct
Astellas Pharma Inc. JP3942400007
2026-10-28 Astellas Pharma Inc. “Astellas Pharma and Audax Biosciences have entered into an exclusive option agreement and license agreement for the cancer immunotherapy program DAX-044.”
28
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hynex® Egel 1.5," a concentrated liquid food with a calorie concentration of 1.5 kcal/mL, designed to accommodate dietary restrictions on intake and fluid intake.”
28
Oct
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-10-27 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtecan) Regarding Postoperative Drug Therapy for HER2-Positive Early Breast Cancer in the EU (263.1KB) PDF file will be displayed in a new window.”
28
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-27 CHUGAI PHARMACEUTICAL CO.,LTD. “Consolidated financial results for the third quarter of the fiscal year ending December 2026.”
28
Oct
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-10-27 Sumitomo Pharma Co.,Ltd. “The cancer drug enzomenib, currently under development, has been designated a "Breakthrough Therapy" by the FDA.”
28
Oct
Astellas Pharma Inc. JP3942400007
2026-10-27 Astellas Pharma Inc. “VEOZA™ (fezolinenant) has been submitted for new drug approval by the Drug Evaluation Center of the National Medical Products Administration of China as a treatment for moderate to severe vasomotor symptoms associated with menopause.”